加载中
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
收盘时
US$6.50
−US$0.22 · -3.27%
盘后
US$6.4924
−US$0.0076 · -0.12%
10月13日 19:40 ET
盘中时间采用ET。市场数据可能有所延迟。
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
日内区间
当前US$6.50
52周区间
当前US$6.50
盘中时间采用ET。市场数据可能有所延迟。
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
日内区间
当前US$6.50
52周区间
当前US$6.50
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 356.93万 USD | 268.59万 USD | 246万 USD | 268.47万 USD | 272.13万 USD |
| 销货成本 | 56.29万 USD | 36.2万 USD | 30.33万 USD | 29.71万 USD | 46.77万 USD |
| 毛利 | 300.64万 USD | 232.39万 USD | 215.67万 USD | 238.77万 USD | 225.36万 USD |
| 研究与开发 | 49.36万 USD | 20.61万 USD | 16.93万 USD | 22.56万 USD | 20.34万 USD |
| 销售、一般及管理费用 | 1034.27万 USD | 927.46万 USD | 865.19万 USD | 553.43万 USD | 502.03万 USD |
| 营业费用 | 1083.63万 USD | 948.07万 USD | 882.12万 USD | 575.99万 USD | 522.37万 USD |
| 利息收入 | — | — | −2772 USD | −232.22万 USD | — |
| 利息支出 | 7.4万 USD | 30.07万 USD | 535.8万 USD | 41.76万 USD | 3.69万 USD |
| 折旧和摊销 | 5.95万 USD | 3.78万 USD | 4.07万 USD | 3.71万 USD | 3.67万 USD |
| 营业利润 | −782.99万 USD | −715.68万 USD | −666.45万 USD | −337.22万 USD | −297万 USD |
| 净利润 | −780.06万 USD | −824.15万 USD | −1462.67万 USD | −478.01万 USD | −302.8万 USD |
公司数据更新于 2026年10月14日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI133.94万0.00%2.3万亿 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF65.84万0.00%954亿 USD0.05%US$232.54-0.42%
iShares Micro-Cap ETFIWC20.57万0.02%13.07亿 USD0.60%US$179.6-1.13%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11万0.10%1.16亿 USD0.73%US$15.6501-1.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
